1. Anti-infection
  2. HCV

HCV

Hepatitis C virus (HCV) is a positive-strand RNA virus grouped in the genus Hepacivirus within the family Flaviviridae. HCV is classified into at least 6 genotypes (gt), and its error-prone polymerase leads to more than 50 subtypes. The long open reading frame, which encodes the HCV polyprotein, is processed by host and viral proteases and gives rise to three structural proteins (the capsid protein core and envelope glycoproteins E1 and E2) and seven nonstructural (NS) proteins (p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B). NS2 and p7 are essential for virus assembly but not RNA replication, whereas NS3 to NS5B are involved in a membrane-associated RNA replicase complex (RC). The NS3 protein is composed of a serine protease and an RNA helicase/nucleoside triphosphatase (NTPase), NS4A serves as a cofactor for NS3 serine protease, NS5B is the RNA-dependent RNA polymerase, and NS5A is considered to play key roles in multiple steps of the HCV life cycle.NS5A inhibitors exhibit a rapid inhibition of virus infectivity shortly after administration to HCV-infected cells.

The HCV protein NS5A prevents the apoptosis-enabling loss of intracellular potassium by inhibiting Kv2.1 function and thus blocking hepatocyte cell death.

The HCV RNA-dependent RNA polymerase (RdRp) has long been a prime target for antiviral development because of its critical role in viral replication and the absence of a mammalian homologous enzyme.

The combination of lucidone and alpha interferon, the protease inhibitor Telaprevir, the NS5A inhibitor BMS-790052, or the NS5B polymerase inhibitor PSI-7977, synergistically suppresses HCV RNA replication.

HCV Related Products (52):

Cat. No. Product Name Effect Purity
  • HY-14434
    Asunaprevir Inhibitor 99.27%
    Asunaprevir is a potent hepatitis C virus (HCV) NS3 protease inhibitor, with the IC50 of 0.2 nM-3.5 nM.
  • HY-15005
    PSI-7977 Inhibitor 99.94%
    PSI-7977 is an active inhibitor of HCV RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (HCV) activity.
  • HY-10241
    Simeprevir Inhibitor 99.98%
    Simeprevir is a potent HCV NS3/4A protease inhibitor, and inhibits HCV replication with EC50 of 8 nM.
  • HY-10466
    Daclatasvir Inhibitor 99.31%
    Daclatasvir is a potent HCV NS5A protein inhibitor, with mean EC50 values of 50 and 9 pM against genotype 1a and 1b replicons, respectively.
  • HY-12594
    Paritaprevir Inhibitor >98.0%
    Paritaprevir is a potent non-structural protein 3/4A (NS3/4A) protease inhibitor with EC50 values of 1 and 0.21 nM for HCV 1a and 1b, respectively.
  • HY-12530
    Velpatasvir Inhibitor 99.71%
    Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons.
  • HY-16134A
    Celgosivir hydrochloride Inhibitor >98.0%
    Celgosivir hydrochloride (MDL 28574A) is an α-glucosidase I inhibitor; inhibits bovine viral diarrhoea virus (BVDV) with an IC50 of 1.27 μM in in vitro assay.
  • HY-12429
    Beclabuvir Inhibitor 99.81%
    Beclabuvir is an allosteric inhibitor that binds to thumb site 1 of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase, and inhibits recombinant NS5B proteins from HCV genotypes 1, 3, 4, and 5 with IC50 of < 28 nM.
  • HY-10235
    Telaprevir Inhibitor 99.89%
    Telaprevir is a highly selective, reversible, and potent peptidomimetic inhibitor of the HCV NS3-4A protease, the steady-state inhibitory constant (Ki) of Telaprevir is 7 nM against a genotype 1 (H strain) NS3 protease domain plus a NS4A cofactor peptide.
  • HY-15602
    Ledipasvir Inhibitor >98.0%
    Ledipasvir is an inhibitor of the hepatitis C virus NS5A, with EC50 values of 34 pM against GT1a and 4 pM against GT1b replicon.
  • HY-10237
    Boceprevir Inhibitor
    Boceprevir is a novel, potent, highly selective, orally bioavailable HCV NS3 protease inhibitor with Ki of 14 nM in both enzyme assay and EC90 of 350 nM in cell-based replicon assay.
  • HY-13997
    Ombitasvir Inhibitor 99.89%
    Ombitasvir is a potent inhibitor of the hepatitis C virus protein NS5A, with EC50s of 0.82 to 19.3 pM against HCV genotypes 1 to 5 and 366 pM against genotype 6a.
  • HY-15298
    MK-5172 Inhibitor 99.58%
    MK-5172 is a selective inhibitor of Hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants, with Ki of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively.
  • HY-13998
    ABT-333 Inhibitor
    ABT-333 is an NS5B non-nucleoside polymerase inhibitor.
  • HY-15789
    Elbasvir Inhibitor 98.20%
    Elbasvir (MK-8742) is a small-molecule inhibitor of nonstructural protein 5A (NS5A) of hepatitis C virus (HCV) being developed as a component of treatment regimens for chronic HCV infection.
  • HY-B0434
    Ribavirin Inhibitor >98.0%
    Ribavirin is synthetic purine nucleoside analogue, and displays well-known antiviral activity against several RNA viruses involved in neurological damage in humans and animals.
  • HY-10444
    R-1479 Inhibitor 99.44%
    R1479 (4'-azidocytidine), is a potent and highly specific inhibitor of HCV replication in cell culture, and that its triphosphate is a potent and highly selective inhibitor of NS5B mediated RNA synthesis, the HCV encoded RNA polymerase.
  • HY-10238
    Danoprevir Inhibitor
    Danoprevir is a peptidomimetic inhibitor of the NS3/4A protease of hepatitis C virus (HCV) with IC50 of 0.2-3.5 nM.
  • HY-B0094
    Artemisinin Inhibitor >98.0%
    Artemisinin, a natural product that is widely used as an anti-malarial drug, is an inhibitor of HCV subgenomic replicon replication.
  • HY-10443
    Balapiravir Inhibitor 98.11%
    Balapiravir (R1626, Ro 4588161) is the prodrug of a nucleoside analogue inhibitor of the hepatitis C virus (HCV) RNA-dependent RNA polymerase (R1479, RG1479).